Roflumilast 0.3% topical foam
Sponsors
Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Harrison Dermatology
Conditions
Hidradenitis Suppurativa (HS)Immune-related Dermatitis
Phase 2
The Safety and Efficacy of Roflumilast Foam in HS
RecruitingNCT07263230
Start: 2026-09-01End: 2029-05-01Target: 20Updated: 2026-07-09
An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors
Not yet recruitingNCT07639840
Start: 2026-08-01End: 2027-11-01Target: 20Updated: 2026-06-10
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Not yet recruitingNCT07689188
Start: 2026-08-10End: 2028-12-10Target: 10Updated: 2026-07-09